Noncoding RNA CCDC26 regulates KIT expression

June 01, 2015

A long noncoding RNA (lncRNA), which might give an impact on tyrosine kinase-targeted leukemia therapy, was found to be expressed in a leukemia cell line. The function of the lncRNA CCDC26 is not fully understood; however, researchers at Hiroshima University revealed the mechanisms by which CCDC26 controls the receptor tyrosine kinase KIT expression. The results provide new insights into leukemia recurrence and may help to develop new leukemia therapies.

Recent transcriptomic studies have revealed the existence of numerous RNAs that are relatively long but not translated into proteins. Some of such lncRNAs are suggested to regulate the expression of other genes. Mutations or imbalances in the noncoding RNA repertoire within the body can therefore cause a variety of diseases such as cancer. However, the molecular functions of lncRNAs remain to be fully elucidated.

Dr. Tetsuo Hirano from the Graduate School of Integrated Arts and Science at Hiroshima University found that knockdown of the CCDC26 gene in cells results in significant upregulation of the KIT gene, hyperactive mutations of which are often found in acute myeloid leukemia.

Dr. Hirano and his collaborators at the School of Medicine in Juntendo University showed that CCDC26 transcript levels are high in the nuclear fraction of human myeloid leukemia cell lines. They also found that CCDC26 knockdown induces suppression of CCDC26 intron-containing transcripts, indicating transcriptional gene suppression. Leukemia cells in which CCDC26 was knocked down showed enhanced survival periods after serum withdrawal. A KIT-specific inhibitor reversed this increased survival of the cells. These results are published in a Molecular Cancer article titled, "Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression."

"We suggested that CCDC26 controls growth of myeloid leukemia cells through regulation of KIT expression. Abnormal CCDC26 RNA structure could modulate the regulation of KIT to induce undesired overexpression. Leukemia characterized by a mutated copy number of CCDC26 might be treated by KIT-targeted therapy" quoted Dr. Hirano.
-end-


Hiroshima University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.